Biotech Corvus expands stock sale agreement with Jefferies, shares down

Corvus Pharmaceuticals

13/03/2026 12:58

** Shares of biotech firm Corvus Pharmaceuticals CRVS.O fall 2% to $15.69 premarket

** Co expands at-the-market stock sale agreement with Jefferies for up to $200 million, doubling the prior $100 million limit set in 2024

** New deal lets CRVS sell shares through multiple methods, including private transactions and block trades, the company said

** CRVS has not sold any shares under the earlier agreement; Jefferies to earn up to 3% commission on any shares sold, according to a filing

** As of last close, stock up about two-fold YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))